Concepts (209)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Crohn Disease | 18 | 2019 | 2303 | 2.030 |
Why?
|
| Colitis, Ulcerative | 13 | 2016 | 1912 | 1.270 |
Why?
|
| Inflammatory Bowel Diseases | 14 | 2022 | 2425 | 1.090 |
Why?
|
| Gastroesophageal Reflux | 7 | 2016 | 782 | 0.650 |
Why?
|
| Actigraphy | 1 | 2019 | 488 | 0.520 |
Why?
|
| Gastrointestinal Agents | 2 | 2016 | 494 | 0.500 |
Why?
|
| Esophageal pH Monitoring | 7 | 2016 | 191 | 0.490 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2016 | 1790 | 0.450 |
Why?
|
| Mesalamine | 3 | 2008 | 136 | 0.430 |
Why?
|
| Biological Products | 2 | 2022 | 860 | 0.410 |
Why?
|
| Azathioprine | 3 | 2008 | 353 | 0.410 |
Why?
|
| Gene Expression Profiling | 3 | 2015 | 9438 | 0.400 |
Why?
|
| Colonoscopy | 7 | 2019 | 1367 | 0.390 |
Why?
|
| Lung Transplantation | 5 | 2017 | 1153 | 0.310 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2007 | 72 | 0.310 |
Why?
|
| Gastrointestinal Motility | 1 | 2008 | 225 | 0.290 |
Why?
|
| Diarrhea | 2 | 2011 | 1348 | 0.270 |
Why?
|
| Interleukin-23 | 1 | 2006 | 193 | 0.250 |
Why?
|
| Colorectal Neoplasms | 4 | 2015 | 6773 | 0.250 |
Why?
|
| Severity of Illness Index | 7 | 2016 | 15540 | 0.250 |
Why?
|
| Triazines | 1 | 2006 | 315 | 0.240 |
Why?
|
| Interleukin-12 | 1 | 2006 | 579 | 0.230 |
Why?
|
| RNA | 1 | 2013 | 2749 | 0.220 |
Why?
|
| Fertilization in Vitro | 3 | 2016 | 1284 | 0.220 |
Why?
|
| Morpholines | 1 | 2006 | 571 | 0.220 |
Why?
|
| Esophagus | 1 | 2008 | 1019 | 0.220 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2003 | 152 | 0.210 |
Why?
|
| Leukocytes | 1 | 2010 | 2043 | 0.200 |
Why?
|
| Remission Induction | 5 | 2016 | 2386 | 0.200 |
Why?
|
| Cross Infection | 1 | 2010 | 1416 | 0.190 |
Why?
|
| Folic Acid | 1 | 2007 | 1300 | 0.190 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 2 | 2016 | 451 | 0.190 |
Why?
|
| Gastrostomy | 1 | 2003 | 309 | 0.180 |
Why?
|
| Length of Stay | 3 | 2019 | 6309 | 0.180 |
Why?
|
| RNA, Messenger | 1 | 2015 | 13033 | 0.180 |
Why?
|
| Patient Readmission | 3 | 2019 | 3114 | 0.180 |
Why?
|
| Infertility | 3 | 2016 | 655 | 0.180 |
Why?
|
| Colitis | 2 | 2004 | 1170 | 0.170 |
Why?
|
| Enteral Nutrition | 1 | 2003 | 763 | 0.150 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2003 | 868 | 0.140 |
Why?
|
| Heartburn | 1 | 2016 | 68 | 0.140 |
Why?
|
| Intestinal Polyps | 1 | 2015 | 100 | 0.130 |
Why?
|
| Proton Pump Inhibitors | 2 | 2017 | 526 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 4751 | 0.130 |
Why?
|
| Electric Impedance | 5 | 2016 | 729 | 0.120 |
Why?
|
| Esophageal Stenosis | 1 | 2016 | 195 | 0.120 |
Why?
|
| Middle Aged | 28 | 2019 | 213383 | 0.120 |
Why?
|
| Eosinophilic Esophagitis | 1 | 2016 | 168 | 0.110 |
Why?
|
| Adult | 26 | 2019 | 214055 | 0.110 |
Why?
|
| Immunosuppressive Agents | 3 | 2016 | 4149 | 0.110 |
Why?
|
| Colonic Pouches | 1 | 2014 | 121 | 0.110 |
Why?
|
| Adenoma | 2 | 2015 | 2174 | 0.110 |
Why?
|
| Aged | 20 | 2019 | 163280 | 0.110 |
Why?
|
| Case-Control Studies | 5 | 2016 | 21746 | 0.110 |
Why?
|
| Patient Compliance | 2 | 2014 | 2684 | 0.110 |
Why?
|
| Graft Rejection | 2 | 2017 | 4397 | 0.110 |
Why?
|
| Humans | 43 | 2022 | 744343 | 0.110 |
Why?
|
| Intestinal Neoplasms | 1 | 2015 | 319 | 0.110 |
Why?
|
| Male | 29 | 2019 | 350118 | 0.100 |
Why?
|
| Female | 32 | 2019 | 380194 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 2 | 2008 | 7181 | 0.100 |
Why?
|
| Sensitivity and Specificity | 3 | 2016 | 14722 | 0.100 |
Why?
|
| Continuity of Patient Care | 1 | 2019 | 1049 | 0.100 |
Why?
|
| Gene Expression Regulation | 1 | 2010 | 12072 | 0.100 |
Why?
|
| Receptors, Interleukin-1 Type II | 1 | 2011 | 11 | 0.100 |
Why?
|
| Aminohydrolases | 1 | 2011 | 18 | 0.100 |
Why?
|
| Eosinophils | 1 | 2016 | 955 | 0.100 |
Why?
|
| Oxo-Acid-Lyases | 1 | 2011 | 22 | 0.100 |
Why?
|
| alpha Karyopherins | 1 | 2011 | 41 | 0.100 |
Why?
|
| Esophagoscopy | 2 | 2016 | 390 | 0.100 |
Why?
|
| Colonic Neoplasms | 2 | 2014 | 2541 | 0.100 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 1 | 2011 | 92 | 0.090 |
Why?
|
| Self Efficacy | 1 | 2014 | 616 | 0.090 |
Why?
|
| Deglutition Disorders | 1 | 2016 | 605 | 0.090 |
Why?
|
| Lung Injury | 1 | 2015 | 436 | 0.090 |
Why?
|
| Colonic Polyps | 1 | 2015 | 542 | 0.090 |
Why?
|
| Prognosis | 5 | 2019 | 29063 | 0.090 |
Why?
|
| Young Adult | 11 | 2019 | 56430 | 0.090 |
Why?
|
| Logistic Models | 5 | 2019 | 13408 | 0.090 |
Why?
|
| Treatment Outcome | 11 | 2016 | 63114 | 0.090 |
Why?
|
| Infertility, Female | 1 | 2016 | 787 | 0.090 |
Why?
|
| Abdominal Pain | 1 | 2016 | 1063 | 0.090 |
Why?
|
| Diagnosis, Differential | 4 | 2016 | 12959 | 0.090 |
Why?
|
| Pennsylvania | 1 | 2010 | 613 | 0.080 |
Why?
|
| Population Surveillance | 2 | 2016 | 2616 | 0.080 |
Why?
|
| Precancerous Conditions | 1 | 2015 | 975 | 0.080 |
Why?
|
| Esophagitis, Peptic | 1 | 2008 | 78 | 0.080 |
Why?
|
| Cholagogues and Choleretics | 1 | 2007 | 32 | 0.080 |
Why?
|
| Comorbidity | 2 | 2019 | 10388 | 0.080 |
Why?
|
| Retrospective Studies | 16 | 2022 | 77449 | 0.080 |
Why?
|
| Tomography, Emission-Computed | 1 | 2010 | 1144 | 0.080 |
Why?
|
| Cross-Sectional Studies | 6 | 2019 | 25043 | 0.070 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2007 | 2282 | 0.070 |
Why?
|
| Thioguanine | 1 | 2006 | 46 | 0.070 |
Why?
|
| Hydrogen-Ion Concentration | 3 | 2016 | 2557 | 0.070 |
Why?
|
| Lung Diseases | 1 | 2016 | 1886 | 0.070 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 6489 | 0.070 |
Why?
|
| Paraneoplastic Endocrine Syndromes | 1 | 1985 | 31 | 0.070 |
Why?
|
| Hydrazones | 1 | 2006 | 102 | 0.070 |
Why?
|
| Respiratory Insufficiency | 1 | 2014 | 1199 | 0.070 |
Why?
|
| Cyclosporine | 1 | 2008 | 786 | 0.070 |
Why?
|
| Vasoactive Intestinal Peptide | 1 | 1985 | 179 | 0.060 |
Why?
|
| Vitamin B Complex | 1 | 2007 | 288 | 0.060 |
Why?
|
| Cytoskeletal Proteins | 1 | 2011 | 1364 | 0.060 |
Why?
|
| Prospective Studies | 5 | 2019 | 53288 | 0.060 |
Why?
|
| Receptors, Immunologic | 1 | 2011 | 1423 | 0.060 |
Why?
|
| Patient Selection | 1 | 2016 | 4215 | 0.060 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2015 | 1855 | 0.060 |
Why?
|
| Pouchitis | 1 | 2004 | 62 | 0.060 |
Why?
|
| Opioid-Related Disorders | 1 | 2018 | 2065 | 0.060 |
Why?
|
| Pheochromocytoma | 1 | 1985 | 337 | 0.060 |
Why?
|
| Cohort Studies | 8 | 2019 | 40561 | 0.060 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 39050 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 3597 | 0.050 |
Why?
|
| Algorithms | 1 | 2003 | 13881 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2010 | 2016 | 0.050 |
Why?
|
| Methotrexate | 1 | 2008 | 1727 | 0.050 |
Why?
|
| Live Birth | 2 | 2016 | 512 | 0.050 |
Why?
|
| Radiopharmaceuticals | 1 | 2010 | 2645 | 0.050 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 3047 | 0.050 |
Why?
|
| Clinical Trials as Topic | 2 | 2006 | 7913 | 0.050 |
Why?
|
| Health Services for the Aged | 1 | 2003 | 269 | 0.050 |
Why?
|
| Antigens, CD | 1 | 2011 | 4026 | 0.050 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1985 | 740 | 0.050 |
Why?
|
| Early Detection of Cancer | 1 | 2013 | 3086 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2011 | 3462 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 11031 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2006 | 3913 | 0.040 |
Why?
|
| ROC Curve | 2 | 2016 | 3527 | 0.040 |
Why?
|
| Florida | 1 | 2019 | 435 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 6364 | 0.040 |
Why?
|
| Aged, 80 and over | 5 | 2018 | 57776 | 0.040 |
Why?
|
| Ethics, Medical | 1 | 2003 | 792 | 0.040 |
Why?
|
| New York | 1 | 2019 | 886 | 0.030 |
Why?
|
| Health Care Surveys | 2 | 2014 | 2453 | 0.030 |
Why?
|
| Colon | 1 | 2004 | 1772 | 0.030 |
Why?
|
| Adolescent | 4 | 2019 | 85781 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 19905 | 0.030 |
Why?
|
| Retreatment | 1 | 2016 | 610 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2010 | 6234 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2006 | 2942 | 0.030 |
Why?
|
| Motivation | 2 | 2014 | 1971 | 0.030 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2016 | 744 | 0.030 |
Why?
|
| Risk Factors | 5 | 2019 | 72290 | 0.030 |
Why?
|
| Physicians | 1 | 2011 | 4567 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2019 | 853 | 0.030 |
Why?
|
| Proctocolectomy, Restorative | 1 | 2014 | 189 | 0.030 |
Why?
|
| Self Report | 2 | 2014 | 3558 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2014 | 549 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 2003 | 1622 | 0.030 |
Why?
|
| Mood Disorders | 1 | 2019 | 1106 | 0.030 |
Why?
|
| Neoplasms | 2 | 2016 | 21683 | 0.030 |
Why?
|
| Hyperplasia | 1 | 2015 | 1185 | 0.030 |
Why?
|
| Cell Count | 1 | 2016 | 1856 | 0.030 |
Why?
|
| Pregnancy Rate | 1 | 2014 | 643 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 9274 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2015 | 1654 | 0.020 |
Why?
|
| Proportional Hazards Models | 2 | 2015 | 12354 | 0.020 |
Why?
|
| Age Factors | 2 | 2019 | 18370 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2015 | 2618 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2010 | 588 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 15076 | 0.020 |
Why?
|
| Time Factors | 3 | 2016 | 40075 | 0.020 |
Why?
|
| Pregnancy | 3 | 2016 | 29144 | 0.020 |
Why?
|
| Hospitalization | 2 | 2019 | 10262 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2010 | 981 | 0.020 |
Why?
|
| Antibodies | 1 | 2016 | 2460 | 0.020 |
Why?
|
| United States | 3 | 2019 | 69872 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2022 | 3749 | 0.020 |
Why?
|
| Inflammation | 1 | 2006 | 10638 | 0.020 |
Why?
|
| Health Services Accessibility | 2 | 2014 | 5137 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2019 | 2494 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2015 | 1580 | 0.020 |
Why?
|
| Capsule Endoscopy | 1 | 2007 | 125 | 0.020 |
Why?
|
| Medicaid | 1 | 2019 | 2736 | 0.020 |
Why?
|
| Radiometry | 1 | 2010 | 800 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 12245 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2019 | 5317 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 6538 | 0.020 |
Why?
|
| Antibodies, Fungal | 1 | 2004 | 32 | 0.020 |
Why?
|
| Monitoring, Ambulatory | 1 | 2007 | 355 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 4420 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 3778 | 0.010 |
Why?
|
| Acute Disease | 1 | 2014 | 7149 | 0.010 |
Why?
|
| Biopsy | 1 | 2015 | 6756 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 13989 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 2022 | 7659 | 0.010 |
Why?
|
| Substance-Related Disorders | 1 | 2019 | 4258 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1985 | 2645 | 0.010 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2004 | 288 | 0.010 |
Why?
|
| Prevalence | 1 | 2018 | 15226 | 0.010 |
Why?
|
| Quality of Life | 1 | 2003 | 12804 | 0.010 |
Why?
|
| Intestines | 1 | 2010 | 1924 | 0.010 |
Why?
|
| Medicare | 1 | 2019 | 6566 | 0.010 |
Why?
|
| Probiotics | 1 | 2004 | 351 | 0.010 |
Why?
|
| Angiography | 1 | 1985 | 1639 | 0.010 |
Why?
|
| Disease Progression | 1 | 2016 | 13284 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 9959 | 0.010 |
Why?
|
| Research Design | 1 | 2015 | 5987 | 0.010 |
Why?
|
| Lung | 1 | 2017 | 9856 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2016 | 12720 | 0.010 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2010 | 3327 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2010 | 8324 | 0.010 |
Why?
|
| Contrast Media | 1 | 2010 | 5300 | 0.010 |
Why?
|
| Incidence | 1 | 2014 | 20947 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2004 | 2752 | 0.010 |
Why?
|
| Ultrasonography | 1 | 1985 | 5985 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1985 | 20129 | 0.000 |
Why?
|
| Child | 1 | 2006 | 77709 | 0.000 |
Why?
|
Concepts
(209)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(34)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_